Analysis BioNTech Faces a Legal Storm as Q1 Revenue Misses and a $1 Billion Buyback Awaits Judgment Day
BioNTech’s stock is caught in a tug-of-war between a robust $1 billion share buyback program and a deepening legal quagmire that now includes a fresh patent lawsuit from Sanofi. The...